LGVN · ISSUER CIK 1721484
Longeveron Inc.
Between Aug 1, 2026 and Oct 29, 2026, 13 Longeveron Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗13 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Oct 5, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 202618:00 | Oct 1, 2026 | LGVN | Chief Financial Officer | F · Tax | $2.59 | −742 | 29,258 | -2% | $2K | ||
| Oct 5, 202618:00 | Oct 1, 2026 | LGVN | Chief Executive Officer | F · Tax | $2.59 | −1,987 | 74,916 | -3% | $5K | ||
| Oct 5, 202618:00 | Oct 1, 2026 | LGVN | Chief Medical Officer | F · Tax | $2.59 | −2,913 | 68,778 | -4% | $8K | ||
| Oct 5, 202618:00 | Oct 1, 2026 | LGVN | General Counsel, Secretary | F · Tax | $2.59 | −2,253 | 83,889 | -3% | $6K | ||
| Oct 5, 202618:00 | Oct 1, 2026 | LGVN | CTO & SVP of CMC | F · Tax | $2.59 | −2,520 | 68,653 | -4% | $7K | ||
| Aug 25, 202618:05 | Aug 17, 2026 | LGVN | Chief Financial Officer | A · GrantLate 8d | — | +300,000 | 300,000 | New | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | General Counsel, Secretary | A · Grant | — | +286,000 | 861,423 | +50% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 69,000 | +109% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 262,034 | +16% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 70,000 | +106% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 77,000 | +88% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 36,000 | New | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 36,000 | New | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | CTO & SVP of CMC | A · Grant | — | +286,000 | 711,735 | +67% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Director | A · Grant | — | +36,000 | 36,000 | New | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Chief Medical Officer | A · Grant | — | +286,000 | 716,914 | +66% | — | ||
| Aug 21, 202618:00 | Aug 19, 2026 | LGVN | Chief Scientific Officer, Director, 10% Owner | A · Grant | — | +286,000 | 1,607,796 | +22% | — |